Congratulations to the June 2014 Graduates

Tracy Yep, PharmD, MS; Carlos Gallego, MD, MS; Katharine Gries, PharmD, PhD; Preeti Bajaj, PhD; Norio Kasahara, MPH, PhD

PORPP ANNUAL REPORT PHARMACEUTICAL OUTCOMES RESEARCH & POLICY PROGRAM

FALL 2014

PORPP Faculty Joseph Babigumira, MBChB, MS, PhD Adjunct Assistant Professor

Aasthaa Bansal, PhD Research Assistant Professor

Anirban Basu, PhD Adjunct Professor, Health Services

Denise Boudreau, PhD Affiliate Professor

Brian Bresnahan, PhD Adjunct Research Associate Professor

Josh Carlson, MPH, PhD Assistant Professor

Emily Beth Devine, PharmD, MBA, PhD, Associate Professor

David Flum, MD, MPH Adjunct Professor

Louis Garrison, Jr., PhD Professor, Interim Director

Bernardo Goulart, MD, MS Adjunct Assistant Professor

Shelly Gray, PharmD, MS Professor

Ryan Hansen, PharmD, PhD Acting Assistant Professor

Thomas Hazlet, PharmD, DrPH Associate Professor

Jerry Jarvik, MD, MPH Adjunct Professor

Larry Kessler, ScD, Professor and Chair, Dept. of Health Services Gary Lyman, MD, MPH Co-Director, HICORE (Hutchinson Insti-tute for Cancer Outcomes Research and Evaluation), Fred Hutchinson Cancer Re-search Center

Jeannine McCune, PharmD Professor

Donald Patrick, PhD Adjunct Professor

Scott Ramsey, MD, PhD Adjunct Profes-sor, Director, HICORE (Hutchinson Insti-tute for Cancer Outcomes Research and Evaluation), Fred Hutchinson Cancer Re-search Center

Andy Stergachis, PhD Adjunct Professor

Sean Sullivan, PhD, Stergachis Family Endowed Professor, Dean of the School of Pharmacy

David Veenstra, PharmD, PhD Professor, Associate Director, PORPP Director, Graduate Programs

Staff Penny Evans Graduate Program Advisor Laurie Gold, PhD Research Scientist Paul Kraegel, MSW Program Operations Specialist

August 14, 2014

MESSAGE FROM LOU GARRISON, PhD

Interim Director

We are pleased to provide you with the annual report of the University of Washington Pharmaceutical Outcomes Re-search and Policy Program (PORPP) cataloging the activities, scholarship, and professional accomplishments of the faculty, staff, graduate students, and post-doctoral fellows. As you will see in reviewing this, PORPP continues to grow in num-ber and in the achievements of its talented and dedicated staff working collaboratively across a wide range of disciplines. As you probably know, we are beginning a period of transi-tion with the ascension of our longstanding Director Sean Sullivan to his new role as Dean of the School of Pharmacy. Under his leadership over the past 15 years, PORPP has been

established as one of the premier programs in this field. We aim to build on that foun-dation as we look to the coming years, including the selection of a new Director. We wish Sean continued success and look forward to supporting him in his new role. We should highlight a few of the more notable achievements of the Program and staff in the past year. Several of our faculty and students received prominent recognition. Professor Josh Carlson received the ISPOR Bernie J. O’Brien New Investigator Award. Professor Beth Devine co-led and was featured at the recent PHRMA Foundation CER conference. Professor Andy Stergachis was named the 2013 Washington State Pharma-cist of the year. Kai Yeung received the Best Student Podium Research Award at the ISPOR International Meeting. And, from the AMCP Foundation, Professor Sean Sulli-van received the Steven G. Avey award for sustained, exemplary and distinguished ser-vice to managed care pharmacy. This coming year, PORPP will welcome our third class of 70+ Distance Learning stu-dents enrolled in the Certificate in Health Economics and Outcomes Research (http://www.pce.uw.edu/certificates/health-economics.html). We have now trained over 120 students. Our faculty and alumni have been generous in support of the program during this past year. The last page of this report lists the PORPP donors for 2013-2014. We heartily thank them for their support. For this coming year, we are admitting another strong new graduate program cohort. Professors Veenstra, Devine, and Hazlet recruited our top candidates, who are profiled here. Also, I am pleased to welcome two new faculty members, Aasthaa Bansal, PhD, Research Assistant Professor, and Gary Lyman, MD, MPH, Professor. Finally, I want to thank Penny Evans and Paul Kraegel, our superb program and re-search coordinators, who help to make all of this possible.

Table of Contents Graduating Class & New Students………………………………………………………...3 Current Students……………………………..……………………………………………...4 Honors & Awards…………………………..……………………………………………….5 Bernie J. O’Brien Award..…………………………………………………………………...6 PORPP Endowed Prize Recipients..……………………………………………………….8 Certificate Programs…………………………………….…………………………………...8 Welcome to New Faculty…………………………...……………………………………….9 Post Doctoral Fellows..………………………………………………………………....…..10 Biomedical Regulatory Affairs Program…….…………………………...…………….…..11 Student Publications…………………….…………………...…………………….……..…11 Post Doc & Faculty Publications………………………...………………………………....12 Faculty Grants…….….……………………………………………………………………....15 Gift Acknowledgements………………………………………………….………………….16

Pharmaceutical Outcomes Research and Policy Program

Department of Pharmacy, University of Washington

Box 357630, Seattle, WA 98195-7630 Phone: 206-616-1383

Fax: 206-543-3835 Email: pennye@uw.edu

http://sop.washington.edu/porpp

Welcome To Our New Students

3 PORPP

Graduating Class of 2014

Master of Science in Pharmacy Degrees

Carlos Gallego, MD, 2003 Universidad del Valle, Colombia; MS 2014 University of Washington Thesis: “Next Generation Sequencing Panels for the Evalua-tion of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis” Chair: David Veenstra, PharmD, PhD

Tracy Yep, BS 2007 University of California, San Diego; PharmD 2012 University of Washington; MS 2014 Universi-ty of Washington Thesis: “Total and Disease Specific Healthcare Cost and Uti-lization of Glaucoma Patients” Chair: Beth Devine, PharmD, MBA, PhD

Doctor of Philosophy in Pharmacy Degrees

Preeti Bajaj, BS 2005 Johns Hopkins University; PhD 2014 University of Washington Dissertation: “Assessing the Impact of HEOR Evidence on Reimbursement Decisions in the U.S.” Chair: Louis Garrison, Jr., PhD Katherine Gries, BS 2004 and MS 2009 University of Wash-ington; PharmD 2008 University of Southern California; PhD 2014 University of Washington Dissertation: “Influence of Perspective on Preferences for Prostate Cancer Outcomes” Chair: Donald Patrick, PhD Norio Kasahara, BS 1991 Tokyo University of Pharmacy & Life Sciences, Japan; MPH 2001 Johns Hopkins University; PhD 2014 University of Washington Dissertation: “Assessing the Availability, Service Quality, and Price of Essential Medicines in Private Pharmacies in Af-ghanistan” Chair: Louis Garrison, Jr, PhD

Blythe Adamson, MPH

Blythe comes from the HIV Vac-cine Trials Network at the Fred Hutchinson Cancer Research Cen-ter where she managed scientific mentoring programs and training on topics ranging from vaccinology to adverse events in clinical trials. She received her Master in Public Health degree in Epidemiology and BS in Honors Microbiology both

from the University of Washington. Previously, Blythe spent four years at the bench in an HIV laboratory studying elite controllers and dual-infection. Her research interests include comparative effectiveness of vaccine candidates and infec-tious diseases math modeling. Blythe is excited to join PORPP to expand her research skillset and become a future leader in the vaccine field.

Simrun Grewal, MPH Simi joins PORPP by way of Johns Hopkins School of Public Health (JHSPH) where she re-ceived her Master of Health Sci-ence in Health Economics (’13) and worked as a Research Asso-ciate in the school’s Department of International Health. While at JHSPH, she conducted economic evaluations on the value of vac-cines, explored individual prefer-

ences related to healthcare decision-making, and examined improved measures of health equity. Prior to her MHS, Simi’s experience included applied approaches to health systems strengthening in sub-Saharan Africa and impact evaluations of maternal and child health programs in Egypt and India. Simi looks forward to continuing her training with PORPP faculty and fellow students. She is particularly interested in strengthening her research capacity in eco-nomic evaluation and pharmacoepidemiology in order to contribute effectively to global essential medicines policies and health service delivery planning. Katelyn Keyloun, PharmD

UW/Allergan Post-Doctoral Fellow 2014 -2016 Katelyn received her PharmD degree from the University of Washington in June 2014. Coming to the pro-gram with a background in parasitol-ogy research, she decided to shift the focus of her research career from enzymology and drug screening in order to learn the techniques and

tools used in outcomes research and policy development. Her interest in outcomes research grew from the desire to blend her knowledge of the pharmacy profession with a career in research and to affect key decisions within organi-zations and the pharmaceutical industry. Katelyn is excited to strengthen her professional career with the UW and Allergan.

Ryan Pistoresi, PharmD Ryan is thrilled to be returning to the University of Washington this year as a student in PORPP. He has already received three degrees from the University of Washing-ton, completing his Doctor of Pharmacy degree in 2014 and earning bachelor’s degrees in Biol-ogy and Biochemistry in 2010. The foundation for Ryan’s passion

in pharmacoeconomics and outcomes research originated from his time studying under PORPP faculty as a pharma-cy student. The subject fascinated Ryan so much that he soon found himself engaged in the field, including initiat-ing

Fall 2014 pg. 4

Current Students Research

ing two research projects and traveling to Montreal to attend ISPOR this past June. Ryan is enthusiastic about the oppor-tunity to study in PORPP and to continue conducting re-search in this field. He hopes to better understand how to properly utilize health economics research and health claims data and how this information can be applied to positively affect decision-making and health policy.

Vanessa Shih, PharmD UW/Allergan Post-Doctoral Fellow 2014-2016

Vanessa received her PharmD degree from the University of California, San Francisco in 2014 where she developed her interest in health services and outcomes research as a member of the Health Services Research and Policy Pathway. She completed her research project on patient preferences in relapsing-remitting multiple sclerosis patients under Leslie Wilson, PhD. She is look-ing forward to joining the PORPP department and learning

from the faculty at UW and Allergan to continue her educa-tion and develop her research skills in order to become an effective health economics and outcomes researcher.

Kangho Suh, PharmD Kangho received his PharmD from Rutgers University in

2011 and then went on to do a health economics and outcomes research fellowship with The University of Texas in Austin, Scott & White Health Plan (SWHP), and Novartis Pharma-ceuticals Corporation. During his time in Texas, he conducted cost analyses for the P&T com-mittee at SWHP and analyzed the clinical and economic im-pact of a pharmacists-led diabe-tes medication management program. In 2013, he complet-

ed a Master’s degree in Pharmacy Administration at UT-Austin with a thesis assessing adherence and perceptions in patients with multiple sclerosis using survey data. While at Novartis, he worked on multiple sclerosis, COPD, and data analysis methods-oriented projects. He is excited to enhance his research skills at PORPP, while learning new statistical and economic methods as he desires to continue a career in the health economics and outcomes research field.

Justin Yu, PharmD UW/Bayer Post-Doctoral Fellow 2014-2016 Justin received his PharmD degree from the University of Southern California in May 2014. As a phar-macy student, he worked as an in-tern in both health-system and am-bulatory care settings – the latter which he credits for first sparking his interest in health economics and outcomes research. His passion for

the field continued to grow after taking managed care and pharmaceutical commercialization electives during his third year, where he gained greater perspective on the value of HEOR to patients and the healthcare system. Carrying this interest forward, he competed in the 2013 AMCP National P&T Competition (3rd place), where his team presented data on the clinical, humanistic, and economic outcomes associat-ed with tapentadol ER in order to make a formulary recom-mendation. Justin is excited to work with the excellent facul-ty at the University of Washington and the Bayer HEOR team, and looks forward to immersing himself in new experi-ences and opportunities.

Maria Agapova, MPH

Maria successfully completed her general exam during her fourth year of the PhD program and continues her work to complete her dissertation, “Quantifying Benefits and Harms of Imaging Tests: The Development of a Framework for Quantitative Method Selection”. She presented the prelimi-nary benefit-harm framework at the Vancouver Health Eco-nomics Conference in June. Maria lead-authored a review related to her dissertation research, published in Academic Radiology, “Applying Quantitative Benefit-Risk Analysis to Aid Regulatory Decision-Making in Diagnostic Imag-ing: Methods, Challenges, and Opportunities”. Maria also lead-authored an article published in Journal of Comparative Effectiveness titled, “Using Indirect Comparisons to Com-pare Interventions within a Cochrane Review: A Tool for Comparative Effectiveness Research”. She collaborated with industry to develop a simplified Excel tool for evaluating cost-benefit of Mirasol Pathogen Reduction Technology across global settings and submitted for publication, the cost-utility findings for the country of Poland, to the Journal of Transfusion Medicine and Hemotherapy. She also contribut-ed to two short papers on value of information analyses in pharmacogenomics.

5 PORPP

Students

Caroline Bennette

R36 Dissertation Grant from AHRQ

NSF Doctoral Dissertation Improvement Grant

Sara Forrester

Finalist for Best Poster Award, Student Category:

Estimating the Inpatient and Outpatient Costs of Atri-al Fibrillation and Associated Adverse Events. For-rester, SH, Sullivan SD, Devine EB. ISPOR 19th Annual Meeting, Montreal, Quebec Can-ada, June 2014

Tracy Yep

Finalist for Best Poster Award, Student Category:

A cost-utility Analysis of CYP2D6 Pharmacogenetic Guided Dosing versus Standard Dosing of Risperi-done for Treatment of Schizophrenia. Yep TD, Devine EB. ISPOR 19th Annual Meeting, Montreal, Quebec Can-ada, June 2014

Kai Yeung

R36 Dissertation Grant from AHRQ

Best Student Podium Research Award: Incentiviz-

ing Value in Managed Care Drug Formularies: De-sign, Implementation, and First-Year Outcomes of a Value-Based Formulary. Watkins J, Sullivan SD, Yeung K, Ramsey S, Garrison L, Wong E, Murphy C, Danielson D, Veenstra D, Vogeler C, Burke W, McGee R. ISPOR 19th Annual Meeting, Montreal, Quebec Can-ada, June 2014

Preeti Bajaj Preeti is currently finishing work on her dissertation, titled "Assessing the Impact of Health Economics and Outcomes Research (HEOR) Studies on Reimbursement Decisions in the United States". She is working with Lou Garrison on her dissertation project, which entails identifying the product-market scenarios for which HEOR evidence has the greatest impact on payer decision-making. Preeti has recently pre-sented her research at the 2014 ISPOR Annual Meeting. In addition, she gave a podium presentation at the National Accountable Care Congress on the topic "Should Pharma-ceutical Companies Share in the 'Accountability'?", and par-ticipated in Merck Serono's Innovation Cup program. Caroline Bennette, MPH Carrie is entering her fourth year of the PhD program. In the last year Carrie successfully passed her general exam and was awarded an R36 Dissertation grant from the AHRQ and a Doctoral Dissertation Improvement Grant from the NSF to support her dissertation. Her dissertation will explore the use of portfolio management techniques to aid in the selec-tion and prioritization of cancer clinical trials. Carrie also continues to work with David Veenstra on the development of a policy model evaluating the cost-effectiveness of return-ing incidental findings from genomic sequencing. In the next year Carrie will complete her dissertation and begin a pos

postdoctoral K12 Mentored Career Development Award in Patient-Centered Outcomes Research, during which time she will pursue additional training and research projects at Group Health Research Institute, the Hutchinson Institute for Cancer Outcomes Research, and UW. Mark Bounthavong, PharmD, MS Mark has been involved with Dr. David Veenstra in the Per-sonalized Medicine Economics Research (PRiMER) project as a research assistant who reviewed the current literature on the competing risks due to drug interaction between amioda-rone and warfarin. In addition, Mark has worked with Dr. Josh Carlson in the Pacific Northwest Evidence-based Prac-tice Center to prepare priority research briefs for PCORI during the academic school year and summer. During the summer, Mark was a graduate-student intern at the Depart-ment of Veterans Affairs where he was responsible for con-structing databases using SQL on the VHA Corporate Data Warehouse. Mark has also started on a meta-analysis investi-gating the efficacy and safety of TNF-alpha inhibitors for moderate-to-severe Crohn's disease with Dr. Beth Devine. At the AcademyHealth Meeting in San Diego, CA (June 2014), Mark presented his work on using multiple imputa-tion methods for handling missing data.

Faculty & Post-Docs

Josh Carlson

2014 ISPOR Bernie J. O’Brien New Investigator Award The ISPOR Bernie O’Brien New Investigator Award was established in 2004 to honor the long-standing commitment of Bernie J. O’Brien, PhD to training and mentoring new scientists in the fields of outcomes research and pharmacoeconomics.

Ryan Hansen & Ryan Oftebro

WSPA Cardinal Health Generation Rx Award for

excellence in prescription drug abuse prevention.

Jean McDougall

PhRMA Post-Doctoral Fellow Award

Sean Sullivan

2014 Steven G Avey Award

The AMCP Foundation Steven G. Avey Award was established in 2001 to recognize an AMCP member for sustained, exemplary and distinguished service to the profession of managed care pharmacy. It is the AMCP Foundation’s highest award.

Andy Stergachis

2013 Washington State Pharmacist of the Year Award Honors a pharmacist who possesses qualities of ex-cellence in routine practice and association activities, is an exemplary role model, and who has contributed in service and skill to the WSPA during the past year.

HONORS AND AWARDS

Fall 2014 pg. 6

Current Students

Will Canestaro, MS

Will is entering his third year of the PhD program and has recently submitted a short proposal for his dissertation. The focus of his research will be developing methods to estimate societal economic loss from publication bias. Will has also spent the past year serving as the research assistant for the federally-funded PriMER study, for which Drs. Carlson and Veenstra are both principal investigators. This has provided an exciting opportunity to learn and build a mixed methods background. Will and his wife Sarah are also expecting their third child, a girl, in November.

Amy Cizik, MPH

Amy has had an exciting and busy 3rd year in the PhD pro-gram, which ended with approval of her dissertation short proposal. Her dissertation will focus on surgeon preferences for the treatment of soft tissue sarcoma; this will include research in the areas of quality of life and cost-utility for the treatment and outcomes of this rare cancer. Aim 1 of her dissertation is primary data collection with sarcoma surgeons at an international meeting held this fall in Berlin, Germa-ny. As a research scientist in the Department of Orthopae-dics and Sports Medicine she continues to collaborate and author papers with surgeons in the field of orthopaedic sur-gical outcomes.

Devender Dhanda, BSPharm, MS, MBA Devender will be entering his second year of the PhD pro-gram in PORPP. He is interested in Value of Information (VOI) studies and Comparative Effectiveness Research (CER). During his first year, Devender refined a decision an-

alytical model for warfarin pharmacogenomics. Currently, he is working on developing a framework for comparing VOI models for drug-drug interaction (warfarin-amiodarone) with warfarin pharmacogenomics. He wants to work further on evaluating the value of conducting additional research for personalized medicine. Katherine Gries, PharmD, MS Katie has completed the data collection and analysis for her dissertation project titled, “Influence of Perspective on Pref-erences for Prostate Cancer Outcomes.” Her final exam is scheduled for fall 2014. During the past year she co-authored the publication, “Current trends in performance-based risk sharing arrangements between healthcare payers and medical product manufacturers” and presented one podium and two poster presentations at congress meetings: “Preferences for Prostate Cancer Outcomes: A comparison of patients and general population perspectives,” “Validation of a novel pa-tient-reported respiratory symptom instrument in cystic fi-brosis: CFRSD-CRISS,” and “A formal approach to evaluate the neuropsychiatric manifestations of PKU: Assessing the content validity of ADHD rating scales in phenylketonuria.” Carlos Gallego, MD, MS Carlos just finished his Masters in Science in PORPP. His interest is in the application of genomic technologies, specifi-cally Next Generation Sequencing into clinical care. His Mas-ters thesis was a cost-effectiveness analysis on the use of Next Generation Sequencing panels for the evaluation of colorectal cancer and polyposis in the medical genetics clinic. He presented part of this work at the American College of Me

PORPP Affiliates Lead the Pack With Four ISPOR Bernie J. O’Brien Awards

The ISPOR Bernie O’Brien New Investigator Award was established in 2004 to honor the long-standing commitment of Bernie J. O’Brien, PhD, to training and mentoring new scientists in the fields of outcomes research and pharmacoeconomics. In the 10 years since inception of the award, four of the ten awardees have been PORPP affiliated schol-ars or are now part of the PORPP faculty. Shelby Reed, PhD

2005 award recipient, 1998-2000 NIH Post-Doctoral Fellow & Re-search Associate, PORPP; Associate Professor in Medicine, Duke Clinical Research Institute

Todd Lee, PharmD, PhD 2007 award recipient, PORPP PhD class of 2001; Associate Profes-sor, University of Illinois, Chicago

Anirban Basu, PhD 2009 award recipient, Adjunct Professor in Pharmacy, PORPP

Josh Carlson, MPH, PhD 2014 award recipient, 2007-2009 Pfizer Post-Doctoral Fellow, PORPP; 2009-2012 Research Assistant Professor, PORPP; 2012-present, Assistant Professor, PORPP

L to R: Todd Lee, Josh Carlson, Shelby Reed, Anirban Basu

Current Students

7 PORPP

PORPP Endowed Prize Recipient

Genetics and the ISPOR meetings, and will present a plat-form this year in the American Society of Human Genetics meeting. In 2014, Carlos published in the Contemporary Journal of Clinical Trials describing a clinical trial evaluating Whole Exome Sequencing in the medical genetics clinic. He also has an interest in health disparities and the access to genomic technology in the Hispanic community. Carlos is a AHRQ/UW K12 research scholar in patient centered out-comes research. Richard Kim, MD, MS Year three of Richard Kim’s PORPP experience has come to a close. Highlights include finishing his term as the UW ISPOR student chapter president, submitting his master’s thesis, and submitting his short proposal. He has had invited commentaries published in the fields of sleep medicine and critical care. With a grant from the Firland Foundation, he is analyzing treatment adherence in non-tuberculous mycobac-terial infections. He presented the clinical outcomes of his multidisciplinary lung nodule clinic at the annual American Thoracic Society meeting this past May. When not devising new ways to get his 3 year old daughter to eat more vegeta-bles, he is building a dataset of regional lung cancer diagnos-tic workup patterns that he will use for his doctoral disserta-tion.

Meng Li, MS

Meng is entering her second year as a PhD student in PORPP. In the past year, she worked with Dr. Hansen on several projects, including a systematic review of health out-comes of organic acidemia patients that is currently under review, a poster presentation on the cost-effectiveness of liver transplantation in methylmalonic and propionic acidemias at ISPOR, and another poster on liver transplanta-tion outcomes among patients with inborn errors of metabo-lism at AST Cutting Edge of Transplantation. Meng was also an invited speaker to the American Thoracic Society 2014 International Conference and she presented her study on the cost-effectiveness of strategies for reducing treatment in mild persistent asthma. This summer, Meng is doing an internship in the US Health Outcome department at GSK. Solomon Lubinga, BPharm, MSc Solomon is entering the third year of the PhD program in PORPP. In the past year, he continued his work with Drs. Andy Stergachis and Joseph Babigumira in the Global Medi-cines Program to support a human resources intervention to strengthen the supply chain of essential medicines in Malawi, implemented by VillageReach, a Seattle based organization. A manuscript describing an impact evaluation of this project is currently in preparation. He also completed two cost-effectiveness analyses. The first, based on his work in the summer of 2013, looking at the cost-effectiveness of intro-ducing second generation antipsychotics for the management of schizophrenia in Uganda is currently under review. In the second, he evaluated the cost-effectiveness of prenatal distri-bu

bution of misoprostol for the prevention of post-partum hemorrhage in Uganda, for which he was a co-recipient of the 2013 PORPP Endowed Prize in Health Policy and Eco-nomics. Solomon also worked with Dr. Ryan N. Hansen of PORPP on a study comparing the outcomes of pain man-agement strategies in bariatric surgery patients, based on an analysis of the Premier Inpatient Database. This work has received a Top Poster Invitation at the 2014 ObesityWeek. This summer, Solomon travelled to Malawi for 3 weeks to support the supply chain strengthening project in Malawi. He will also work on preparing his short dissertation pro-posal. Marita Mann, MPH Marita completed her second year in the PhD program, and successfully completed all of her required coursework. Marita has been refining her dissertation proposal on evalu-ation of an active surveillance program for HIV drugs in Namibia under the guidance of Dr. Andreas Stergachis. Marita submitted her short proposal and selected her com-mittee members in early 2014. Her general exam is sched-uled for August 2014. In the fall she plans to travel to Na-mibia to complete data collection. Marita also spent the past academic year as a TA for the distance learning certificate program, which she will continue next year. Cara McDermott, PharmD, MS Cara will be presenting a poster in October at the Society for Medical Decision Making's annual meeting; the research topic is a systematic review and meta-analysis of directly observed therapy for hepatitis C treatment. This year she plans to prepare for her general exam and work on her dis-sertation focusing on end of life care in older adults with cancer. Elisabeth Vodicka, MPH Elisabeth is entering her second year in the PhD program in PORPP. During her first year, Elisabeth was awarded an AHRQ T32 Health Services Research Pre-Doctoral Fellow-ship. She also published a first-authored manuscript in Jour-nal of Medical Internet Research that evaluated patients' con-cerns about privacy when having online access to their clini-cal notes. She presented this work as a poster at Acade-myHealth, where she also participated in the NRSA Trainee Meeting. Elisabeth worked on a number of other projects this year, including design of a program evaluation for a maternal health training program in Ghana under the guid-ance of Andy Stergachis and a project evaluating the use of patient-reported outcomes in clinical trials with Beth Devine and Donald Patrick. Over the summer, Elisabeth worked with the Treatment Research and Expert Education (TREE) program in Kenya to design and conduct a cost-finding study of cervical cancer screening methods with Joseph Babigumira, Michael Chung, and Lou Garrison.

Fall 2014 pg. 8

Update on the PORPP Certificate Programs

Certificate in Health Economics and

Outcomes Research

The Certificate in Health Economics and Outcomes Research program successfully concluded its second year, with 64 stu-dents completing the program. This distance learning program is designed for professionals working in health care settings includ-ing payer organizations, health insurance industry, government, the life sciences, pharmaceutical and biomedical industries, and for professionals working within Health Technology Assessment or reimbursement organizations. There are 70+ students enrolled for the 2014-2015 session. The program offers one course per academic quarter--Fall quarter: Principles of Health Economics, taught by Lou Garrison and Anirban Basu; Winter quarter: Eco-nomic Evaluation, taught by Dave Veenstra and Josh Carlson; Spring quarter: Practice of HTA in a Global Environment, taught by Sean Sullivan and Rafael Alfonso. During the program, stu-dents learn the key economic concepts and analytical tools of human economic behavior, explore the current state-of-the-art in the economic evaluation of health care technologies, and are introduced to the principles and methods of HTA practice. Stu-dents work in groups throughout the program on a capstone project, which applies their learning to an assigned country. Stu-dent evaluations throughout the year have been positive, noting asynchronous learning design and faculty-developed content as major factors in their satisfaction. Visit: http://www.pce.uw.edu/certificates/health-economics.html for additional information.

UW Center of Excellence in Comparative Effectiveness Research

Led by Lou Garrison, Beth Devine, and Anirban Basu, the UW has now completed the second year of the UW Center of Excel-lence in Comparative Effectiveness Research (CER), the corner-stone of which is the Graduate Certificate in CER. The Certificate is open to currently enrolled PhD and MS students in PORPP and Health Services. Coursework beyond the core work required for each degree prepares enrolled students to execute projects that use advanced skills in observational data analysis and deci-sion sciences, preference (utility) estimation from patient report-ed outcomes data, network meta-analysis, and Bayesian statis-tics. To date, six students have registered to complete the Certifi-cate; three of these have been supported by the formal research assistantships, offered in conjunction by the Pharmaceutical Research and Manufacturer’s Association (PhRMA) Foundation. An additional four have each received a $10,000 dissertation stipend. See http://sop.washington.edu/porpp/certificate-programs/graduate-certificate-in-comparative-effectiveness-research.html for additional information.

In January 2014, Beth Devine and Lou Garrison joined Jodi Segal of Johns Hopkins in leading a national invitational confer-ence titled, “Curricular Advances for Patient-Centered CER”. 120 attendees representing 50 academic institutions, the life sciences industries, the Federal government, professional organizations and health plans discussed approaches used to prepare a work-force skilled in CER and patient centered outcomes research (PCOR). The conference was supported by grants from AHRQ, PCORI, and the PhRMA Foundation. The conference report may be accessed on the website by going to this link: PhRMA Foun-dation. OR: http://phrmafoundation.org/Index.php?option= com_content&view=article&id=100&itemid=41

The UW Center for Excellence in CER has led to two new initia-tives now under development: 1) a stakeholder-driven education-al and experiential training program to prepare scientists and clinicians to conduct CER/PCOR in the WWAMI (Washington, Wyoming, Alaska, Montana, Idaho) region, with a focus on Amer-ican Indians and Alaska Natives, and 2) a certificate program in Translational Sciences. The first is supported by a grant from AHRQ, with Larry Kessler as PI; the second is supported by the Institute of Translational Health Science (UW CTSA), with Beth Devine as Lead Faculty.

Tracy Yep, PharmD, MS Tracy has finished the first year of the UW-Allergan fellow-ship and will spend the second year at the Allergan campus in Irvine, Ca. Over the past year Tracy has worked to complete her master’s degree with a thesis titled: “Total and Disease Specific Resource Use and Healthcare Cost of Patients with Glaucoma.” She also presented work completed with advisor Dr. Beth Devine at the 19th Annual ISPOR conference in Montreal, Canada. Her poster titled: “A Cost Utility Analysis of CYP2D6 Pharmacogenetic Guided Dosing vs Standard Dosing of Risperidone for Treatment of Schizophrenia,” received a student poster finalist ribbon at the conference. Tracy will be working with the ocular department in the coming year and is looking forward to getting involved with projects and furthering her knowledge of outcomes research through her experience at Allergan. Kai Yeung, PharmD, MS Kai Yeung has completed his third year in the PhD program. During this academic year, Kai has successfully passed all his preliminary exams as well as his general exam. Kai’s disserta-tion focuses on the evaluation of the impact a novel value-based formulary which uses cost-effectiveness analysis to determine drug copayments. Related to this work, Kai gave a podium presentation on “Incentivizing value in managed care drug formularies: design, implementation, and first-year out-comes of a value-based formulary” at the annual meeting of the International Society for Pharmacoeconomics and Out-comes Research. This presentation received ISPOR’s best student podium research presentation award. Kai has also successfully completed a NIH funded, 1 year multidiscipli-nary predoctoral clinical research training grant offered through the Institute of Translational Health Sciences and has applied for a dissertation grant through the Agency for Healthcare Research and Quality which is pending review. Kai is very grateful to his mentors at PORPP for their advise-ment.

Current Students

PORPP Endowed Prize Recipients

The PORPP Endowed Prize was given to two stu-dents this year. Both Solomon Lubinga and Marita Mann had winning papers and they each received $500. The title of Solomon’s paper was: “Potential Cost-Effectiveness of Prenatal Distribution of Miso-prostol for Prevention of Post Partum Hemorrhage in Uganda.” Marita’s paper was titled: “Assessing the Potential Cost-effectiveness of Alternative Methods to Screen for Cervical Cancer among HIV-Positive Women in Kenya.” The $1,000 Prize is awarded to eligible candidates in the PhD or Master’s program in PORPP, or related fields such as Public Health Genetics, Health Services, Economics or Global Health who are enrolled in a class taught by a PORPP faculty member. The paper must deal with an original health policy or health eco-nomic issue.

9 PORPP

Welcome New Faculty

Aasthaa Bansal, PhD

Aasthaa is a Research Assistant Professor in the Department of Pharmacy. She received her PhD in biostatistics from the University of Washington and her current research interests include comparative effective-ness research, biomarker devel-opment & evaluation, and per-sonalized medicine. Over the past year, she has col-laborated on several projects at

the Hutchinson Institute for Cancer Outcomes Research (HICOR) at the Fred Hutchinson Cancer Research Center and at the UW. At HICOR, she has been involved in pro-jects including analyses of survival, costs and resource utiliza-tion among prostate cancer patients and among colorectal cancer patients, development of methods using cure model-ing in economic analysis, analyses relating to bankruptcy among cancer patients and analyses of cancer treatment and outcomes among American Indians. On these projects, she has collaborated with Scott Ramsey, Jeannine McCune, Ber-nardo Goulart and Jean McDougall. At the UW, she is involved in a project to develop a mito-chondrial biomarker for cancer detection and prediction in ulcerative colitis. Aasthaa is also actively working on devel-oping statistical methods for prognostic biomarkers and risk prediction models using censored survival data. In the past year, she has had nine articles published or accepted in peer-reviewed journals. She has also had one book chapter pub-lished relating to her dissertation work on combining bi-omarkers to improve performance in diagnostic medicine. Additionally, Aasthaa has served as a statistical consultant and mentor in PORPP and the Department of Pharmacy, providing statistical advice to faculty, postdoctoral fellows and students. She is currently serving on the doctoral com-mittees of PORPP students Cara McDermott (dissertation title: Imaging, treatment, and mortality in lung cancer pa-tients in Washington State, 2002-2010) and Will Canestaro (dissertation title: Calculating the clinical and economic im-pact of publication bias in a historical case).

Gary Lyman, MD, MPH

Gary H. Lyman MD, MPH, is Co-Director of the Hutchinson Institute for Cancer Outcomes Research and Member of the Public Health Sciences and Clinical Research Divisions at the Fred Hutchinson Cancer Research Center. He is also Adjunct Professor in the School of Pharmacy and the School of Public Health at the University of Washington as well as Pro-fessor of Medicine in the Department of Medicine in the University Of Washington School Of Medicine. Dr Lyman is a Medical Oncologist and Hematologist and a member of the Breast Cancer Program at the Seattle Cancer Care Alliance. He was most recently Director of Comparative Effectiveness and Outcomes Research-Oncology at Duke University and the Duke Cancer Institute where he also served as Professor of Medicine in the Duke University School of Medicine and a Senior Fellow at the Duke Center for Clinical Health Policy Research. In addition to his training in Internal Medicine at UNC-Chapel Hill and Hematology/Oncology at Roswell Park Cancer Institute, Dr Lyman was a Postdoctoral Fellow in Biostatistics at the Harvard School of Public Health. Dr Lyman is also a member of the ASCO Research Committee, Biomarkers Guideline Working Group, the Comparative Effectiveness Research Task Force and the Value of Cancer Care Task Force contributing to development of ASCO’s Top Five as a part of the ABIM Choosing Wisely Campaign. He is Editor-In-Chief of Cancer Investigation and on the Editorial Board of the Journal of Clinical Oncology and several other spe-cialty journals. His research interests include comparative effectiveness and outcomes research related to targeted ther-apies and biomarkers, efforts to integrate health economics into evidence-based medicine, health policies and real world research paradigms. His research group is also engaged in advanced methods of evidence synthesis in support of clini-cal practice guidelines and population studies of patterns of cancer treatment and the impact of health disparities on the quality of cancer care.

Back to the Future The 2014 PORPP/ISPOR Reception in Montreal had some of the original PORPP graduates meeting our newest crop of students. Many enjoyed a few pints of Guinness at McKibbin’s Irish Pub, and a good time was had by all. Sláinte!

Post-Doctoral Fellows

2014 PORPP Retreat at Talaris Conference Center

Fall 2014 pg. 10

Souvik Banerjee, PhD

Souvik will join the PORPP-Pfizer postdoctoral fellowship program in Fall, 2014 after completing his PhD in Economics from University at Albany, SUNY. In his dissertation he is examining the impact of mental illness on labor market outcomes like employment and labor supply, using a latent continuous measure for mental illness. Souvik has presented his work at the Ifo/CESifo Confer-ence on Empirical Health Economics, Munich, Germany and also at the Annual Health Economet-rics Workshop, Chapel Hill, NC in 2013. In the position as a postdoctoral fellow he will be working under the primary supervision of Louis Garrison and will also be mentored by Sean Sullivan and Anirban Basu. In the summer of 2015 he is expected to work with Dick Willke at Pfizer, New York, NY for about 3 months. Before joining the program at UW he will meet with Dick Willke to discuss future projects of mutual interest.

Jean McDougall, PhD

Jean received her PhD in Epidemiology from the University of Washington in 2013. Her primary research focus has been on understanding social and economic determinants of the receipt of guide-line-concordant cancer care. Her work in investigating socioeconomic disparities in breast cancer screening and treatment won a Komen Scholar-in-Training Award to present her research at the American Association for Cancer Research Science of Health Disparities Conference held in San Diego, CA in 2012. Jean is working with Sean Sullivan and Scott Ramsey on a diverse set of projects including an analysis of the costs, resource utilization, and impact on survival of skeletal related events among men with prostate cancer, an economic evaluation of alternative breast cancer screen-ing modalities for high risk women, and an analysis of risk factors for bankruptcy among cancer patients.

Julia Slejko, PhD

Julia has concluded the second year of her PORPP-Pfizer postdoctoral fellowship. In November, she presented her work on adherence modeling at ISPOR Europe and the paper Dynamic Medication Adherence Modeling in Primary Prevention of Cardiovascular Disease: A Markov Microsimulation Methods Appli-cation has recently been published in Value in Health. Over the past year she has worked with Dick Willke and the Pfizer pharmacometric modeling group to develop a health economic microsimula-tion model of COPD. She has recently been working with Sean Sullivan, Anirban Basu, Lou Garri-son and Preeti Bajaj on the Health Tech Fund projects, assessing the impact of HEOR studies on the commercial success of drug products. She has accepted a faculty position at the University of Maryland Baltimore in the Pharmaceutical Health Services Research Department to begin this Fall.

PORPP Student

11 PORPP

erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis. JMedEcon 2014 April; 1-9

WILL CANESTARO Canestaro WJ, Patrick AR, Avorn J, Ito K, Matlin OS, Brennan TA, Shrank WH, Choudhry NK. Cost-effectiveness of oral anticoagulants for treatment of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2013 Nov 1;6(6):724-31. Desai NR, Canestaro WJ, Kyrychenko P, Chaplin D, Mar-tell LA, Brennan T, Matlin OS, Choudhry NK. Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention. Circ Cardiovasc Qual Outcomes. 2013 Nov 1;6(6):694-9. CanestaroW, Austin M, Thummel K. Genetic factors af-fecting statin concentrations and subsequent myopathy: a HuGENet systematic review. GenetMed 2014 May; doifind-er/10.1038/gim.2014.41

AMY CIZIK Manoso MW, Cizik AM, Bransford RJ, Bellabarba C, Chap-man J, Lee MJ. Medicaid Status is Associated With Higher Surgical Site Infection Rates After Spine Surgery. Spine (Phila Pa 1976). 2014 Jun 30. [Epub ahead of print] PMID: 24983931 [PubMed - as supplied by publisher] Gundle KR, Cizik AM, Punt SE, Conrad EU 3rd, Davidson DJ. Validation of the SF-6D Health State Utilities Measure in Lower Extremity Sarcoma. Sarcoma. 2014;2014:450902. doi: 10.1155/2014/450902. Epub 2014 Mar 19. PMID: 24771999 [PubMed] Free PMC Article Lee MJ, Cizik AM, Hamilton D, Chapman JR. Predicting medical complications after spine surgery: a validated model using a prospective surgical registry. Spine J. 2014 Feb 1;14(2):291-9. doi: 10.1016/j.spinee.2013.10.043. Epub 2013 Nov 13. PMID: 24239799 [PubMed - in process]

CARLOS GALLEGO Gallego CJ, Bennette CS, Heagerty P, Comstock B, Horike-Pyne M, Hisama F, Amendola LM, Bennett RL, Dorschner MO, Tarczy-Hornoch P, Grady WM, Fullerton SM, Trinidad SB, Regier DA, Nickerson DA, Burke W, Patrick DL, Jarvik GP, Veenstra DL. Comparative effectiveness of next genera-tion genomic sequencing for disease diagnosis: Design of a randomized controlled trial in patients with colorectal can-cer/polyposis syndromes. Contemp Clin Trials. 2014 Jul 3;39(1):1-8. doi: 10.1016/j.cct.2014.06.016. [Epub ahead of print] PMID: 24997220 [PubMed - as supplied by publisher]

Jarvik GP, Amendola LM, Berg JS, Brothers K, Clayton EW, Chung W, Evans BJ, Evans JP, Fullerton SM, Gallego CJ, Garrison NA, Gray SW, Holm IA, Kullo IJ, Lehmann LS, McCarty C, Prows CA, Rehm HL, Sharp RR, Salama J, Sanderson S, Van Driest SL, Williams MS, Wolf SM, Wolf WA; eMERGE Act-ROR Committee and CERC Commit-tee; CSER Act-ROR Working Group, Burke W. Return of genomic results to research participants: the floor, the ceil-ing, and the choices in between.

The School of Pharmacy’s Biomedical Regulatory Affairs Master of Science (BRAMS) program admitted its first class in 2008 and will graduate its 100th student this coming year. An outgrowth of two long-standing certificate programs, Biomedical Regulatory Affairs and Clinical Trials, BRAMS is unusual with its focus on all medical products – biologics, drugs, medical devices – and draws students from both local industry and the Food and Drug Administration, as well as international students (Canada, China, Egypt, India, Japan, Jordan, and Taiwan). The MS degree includes a practicum, and is typically completed in two years. BRAMS faculty have been active participants in the on-going development of a national accrediting organization, Association of Graduate Regulatory Educators.

Employers of our graduates, many hired from the practicum,

include:

Biomedical Regulatory Affairs Program

Amgen (3) Applied Precision, Inc. bioMerieux

Bio-Rad Laboratories ComplianceOnline

Coulter Program (2) CTI (2) Dendreon

EKOS Corporation Eurofins Lancaster Laboratories (for Amgen)

FDA

Fred Hutchinson(2) Genentech Genoa Healthcare

Gilead Sciences Group Health Research Insti-tute Health Canada Skagit Regional Hospital

IDRI IPSEN KLS Martin Kona Medical Inc.

L'Oreal Research and Innovation

Luye Pharma Group, Beijing Metagenics Microsoft Mycenax Biotech, Inc., Taiwan NanoString Natus Medical Inc. Paccar Philips (3) Physio-Control Puget Sound Blood Center Quorum Review Sarepta Therapeutics

Seattle Cancer Care Alliance Seattle Children's Hospital (2) Seattle Genetics(3) Self-employed SonoSite Stanford University Stephens and Associates

Swedish Medical Center (2) The Medicines Company UW (3) WiseWoman Herbals, Bastyr faculty

MARIA AGAPOVA Agapova M, Devine B, Bresnahan B, Garrison L. Applying Quantitative Benefit-Risk Analysis to Aid Regulatory Deci-sion-Making in Diagnostic Imaging: Possible Methods and Challenges. Academic Radiology 21 (2014), pp. 1138-1143. Vahidnia F, Hirschler NV, Agapova M, Chinn A, Busch MP, Custer B. Cancer Incidence and Mortality in a Cohort of US Blood Donors: A 20-Year Study. J Cancer Epidemiol, (2013) pp. 814-842 Agapova M, Devine EB, Inoue L, Nguyen H, Wolf FW. Re-analysis of a Cochrane Meta-analysis in a Bayesian Frame-work: A Contribution to Comparative Effectiveness Re-search. (accepted at Journal of Comparative Effectiveness Research)

PREETI BAJAJ Bajaj PS, Veenstra DL, Goertz HP, Carlson JJ. Targeted

Faculty — Recent Publications

Fall 2014 pg. 12

Post-Doc Publications

ELISABETH VODICKA Vodicka E, Mejilla R, Leveille SG, Ralston JD, Darer JD, Del-banco T, Walker J, Elmore JG. “Online Access to Doctors' Notes: Patient Concerns About Privacy.” J Med Internet Res 2013;15(9):e208. doi:10.2196/jmir.2670.

KAI YEUNG Carlson JJ, Gries KS, Yeung K, Sullivan SD, Garrison LP Jr. Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical prod-uct manufacturers. Appl Health Econ Health Policy. 2014 Jun;12(3):231-8.

JULIA SLEJKO Slejko JF, Sullivan PW, Nair KV, Ho PM, Anderson HD, Campbell JD. Dynamic medication adherence modeling in primary prevention of cardiovascular disease: A Markov mi-crosimulation methods application. Value in Health. (In Press) Slejko JF, Ghushchyan VH, Sucher, B, Globe DR, Lin S-L, Globe G, Sullivan PW. Asthma control in the U.S., 2008-2010: Indicators of poor asthma control. The Journal of Allergy and Clinical Immunology. 2014; 133(6):1579-1587. Slejko JF, Anderson HD, Nair KV, Sullivan PW, Campbell JD Adherence to Statins in Primary Prevention: Yearly Ad-herence Changes and Outcomes. Journal of Managed Care Phar-macy. 2014; 20(1):51-57

JOSEPH BABIGUMIRA Babigumira JB, Stergachis A, Choi HL, Dodoo A, Nwokike J, Garrison LP. A Framework for Assessing the Return on Investment in Pharmacovigilance in Low- and Middle-Income Countries. Drug Safety. 2014 Mar;37(3):127-34.

AASTHAA BANSAL Vanderhoeven J, McAdams RM, Beyer RP, Bammler TK, Farin FM, Rajagopal L, Kapur RP, Bansal A, Spencer M, Deng M, Gravett MG, Rubens CE, Adams Waldorf KM (2014). Group B streptococcal infection of the choriodecidua induces dysfunction of the cytokeratin network in amniotic epithelium: A pathway to premature membrane rupture. PLoS Pathogens, 10(3): e1003920. Weinert C, Cudney S, Comstock B, Bansal A. A computer-based intervention for illness self-management among rural women with chronic health conditions: A randomized paral-lel-group study. Canadian Journal of Nursing Research, in press. Khandelwal N, Hough CL, Bansal A, Veenstra DL, Treggia-ri MM. Long-term survival in patients with severe acute res-piratory distress syndrome and rescue therapies for refractory hypoxemia. Critical Care Medicine, in press.

ANIRBAN BASU Basu A. Chan KCG. Can we make smart choices between OLS versus Contaminated IV estimators? Health Economics

Am J Hum Genet. 2014 Jun 5;94(6):818-26. doi: 10.1016/j.ajhg.2014.04.009. Epub 2014 May 8. PMID: 24814192 [PubMed - indexed for MEDLINE] Related citations Select item 24055113 4 Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, Kim JH, Rosenthal EA, Kim DS; National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project, Tabor HK, Bamshad MJ, Motulsky AG, Scott CR, Pritchard CC, Walsh T, Burke W, Raskind WH, Byers P, Hisama FM, Nickerson DA, Jarvik GP. Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet. 2013 Oct 3;93(4):631-40. doi: 10.1016/j.ajhg.2013.08.006. Epub 2013 Sep 19. PMID: 24055113 [PubMed - indexed for MEDLINE] Free PMC Article Relat-ed citations Select item 23743551 5.

KATHERINE GRIES Carlson, JJ, Gries, K., Yeung, K., Sullivan, SD., Garrison, LP. Current Status and Trends in Performance-Based Risk-Sharing Arrangements between Healthcare Payers and Medi-cal Product Manufacturers . Applied Health Economics and Health Policy. 2014, In Press.

RICHARD KIM Kim R, Kapur VK. “Emerging from the shadows: a possi-ble link between sleep apnea and cancer.” Journal of Clinical Sleep Medicine. 2014;10(4):363-4. Kim R, Goss CH. “Unintended consequences of therapy in the intensive care unit.” JAMA: Internal Medicine. 2014; 174(4):574-6.

MENG LI

Wu Y, Zhou Q, Xuan J, Li M, Zelt S, Huang Y, Yin H, Huang M. A Cost-Effectiveness Analysis Between Amlodi-pine and Angiotensin II Receptor Blockers in Stroke and Myocardial Infarction Prevention Among Hypertension Pa-tients in China. Value in Health Regional Issues. 2013(5);2(1):75-80

MARITA MANN Kantor R, Bettendorf D, Bosch RJ, Mann M, Katzenstein D Cu-Uvin S, D'Aquila R, Frenkel L, Fiscus S, Coombs R; ACTG A5077 Study Team. HIV-1 RNA levels and antiretro-viral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077. PLoS One. 2014 Apr 3;9(4):e93537. doi: 10.1371/journal.pone.0093537. eCollection 2014. Mann M, Diero L, Kemboi E, Mambo F, Rono M, Injera W, Delong A, Schreier L, Wools-Kaloustian K, Sidle J, Buzi-ba N, Kantor R. Antiretroviral treatment interruptions in-duced by the Kenyan postelection crisis are associated with virological failure. J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):220-4. doi: 10.1097/QAI.0b013e31829ec485. Erra-tum in: J Acquir Immune Defic Syndr. 2013 Nov 1;64(3):323. Kaloustian, Kara W [corrected to Wools-Kaloustian, Kara]. PMID: 24047971

13 PORPP

2014; 23(4):462-72. Basu A. Personalized Medicine in the Context of Compara-tive Effectiveness Research. Forum for Health Economics and Policy 2013; 16(2): 107-120.

Basu A, Jena AB, Goldman DP, Philipson TJ, Dubois R. Heterogeneity in action: Role of passive personalization in comparative effectiveness research. Health Economics (with Discussions) 2013; 23(3): 359 – 373.

DENISE BOUDREAU Raebel MA, Newcomer SR, Bayliss EA, Boudreau DM, DeBar L, Elliott TE, Ahmed A, Pawloski PA, Fisher D, Toh S, Donahoo WT. Chronic Opioid Use Emerging after Bari-atric Surgery. Pharmacoepidemiol Drug Saf. 2014. In press. Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJA, Fujii M, Buist DSM. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat. 2014 Feb 21. [Epub ahead of print] Roth JA, Boudreau D,* Fujii MM, Farin FM, Rettie AE, Thummel KE, Veenstra DL. Genetic risk factors for major bleeding in long-term Warfarin patients in a community set-ting. Clinical Pharmacology & Therapeutics. 2014. In press.

BRIAN BRESNAHAN Bresnahan, BW, Rundell, SD, Dagadakis, MC, Sullivan, SD, Jarvik, JG, Nguyen, H, Friedly, JL. Assessing epidural steroid injections for lumbar spinal stenosis: systematically reviewing the comparative literature and estimating reimbursement amounts, PM&R, August 2013; 5:705-714. Bresnahan, BW and Garrison, LP Jr.. Diagnostic imaging, Economic issues in: Anthony J Culyer (ed.), Encyclopedia of Health Economics, Vol. 1. San Diego: Elsevier; 2014. pp.189-199. Cronin P, Kelly A, Sanelli P, Lee J, Heilbrun M, Bresnahan BW, Rawson J, Paladin A, How to Report a Research Study and Appraise the Literature, Acad Rad, August 2014, (epub ahead of print).

JOSH CARLSON Roth, JA., Billings, P., Ramsey, SD., Dumanois, R., Carlson, JJ. Cost-Effectiveness of a 14-Gene Risk Score Assay to Target Adjuvant Chemotherapy in Early Stage Non-Squamous Non-Small Cell Lung Cancer. The Oncologist. 2014, In Press. Carlson, JJ., Gries, K., Yeung, K., Sullivan, SD., Garrison, LP. Current Status and Trends in Performance-Based Risk-Sharing Arrangements between Healthcare Payers and Medi-cal Product Manufacturers . Applied Health Economics and Health Policy. 2014, In Press. Towse, A, Ossa, D, Veenstra, DL, Carlson, JJ, Garrison, LP. Understanding the Economic Value of Molecular Diag-nostic Tests: Case Studies and Lessons Learned. J. Pers. Med. October, 2013.

BETH DEVINE Agapova M, Devine EB, Nguyen H, Inoue L, Wolf F. Com-paring results of frequentist and Bayesian approaches to ex-plore the comparative effectiveness of subgroups in a

Cochrane Systematic Review (in press at J Comp Eff Res, May 2014) Forrester S, Hepp Z, Roth J. Wirtz HS, Devine EB. Cost-effectiveness of a computerized provider order entry system in improving medication safety in ambulatory care. Value Health, 2014 Jun;17(4):340-9. doi: 10.1016/j.jval.2014.01.009. Epub 2014 May 5 *Publication recognized with press release from ISPOR Value in Health, May 2014 Lau B, Overby CL, Wirtz HS, Devine EB. Use of a clinical decision support tool in the ambulatory setting to improve adherence to national monitoring guidelines for medication-laboratory tests. Appl Clin Inf 2013 Oct 16;4(4):476-98. doi: 10.4338/ACI-2013-06-RA-0041.

LOUIS GARRISON, JR. Garrison LP, Jr. (co-chair); Towse A (co-chair) et al. Per-formance-Based Risk-Sharing Arrangements—Good Practic-es for Design, Implementation, and Evaluation: Report of the ISPOR Good Practices for Performance-Based Risk-Sharing Arrangements Task Force, Value in Health, August, 2013 Garrison LP and Towse A. Economics of Personalized Medicine: Pricing and Reimbursement Policies as a Potential Barrier to Development and Adoption. Chapter in: Culyer T, editor. Encyclopedia of Health Economics. Oxford: Else-vier; 2014. Garrison LP. Pharmacoeconomics and Drug Pricing. Chapter 8 in Ho and Gibaldi’s Biotechnology and Biophar-maceuticals: Transforming Proteins and Genes into Drugs, Second Edition, Rodney J. Y. Ho and Milo Gibaldi, John Wiley and Sons, 2013

SHELLY GRAY Lo-Ciganic WH, Boudreau R, Gray SL, Zgibor JC, Donohue JM, Perera S, Strotmeyer E, Bunker CH, Newman AB, Simonsick E, Bauer DC, Satterfield S, Hanlon JT for the Health ABC Study. Time-Trend Utilization of Cholesterol-Lowering Medications in Community-Dwelling Older Adults: Impact of the 2002 National Cholesterol Education Program Guidelines and the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Ann of Pharmacother 2013 In press Gray SL, Anderson M, Hubbard R, LaCroix A, Crane P, McCormick W, Bowen J, McCurry S, Larson EB. Frailty and Incident Dementia. Gerontol A: Biol Sci Med Sci 2013 In press

RYAN HANSEN Montenovo MI, Hansen RN, Dick AAS. Outcomes of Adult Liver Re-Transplant Patients in the MELD Era: Is it Time to Reconsider its Indications? Clinical Transplantation. In Press. July 2014. Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to Oral Migraine Preventive Medica-tions Among Patients with Chronic Migraine. Cephalagia. In Press. June 2014. Luxton DD, Hansen RN, Stanfill KE. Mobile App Self-care versus In-office Care for Stress Reduction: A Cost Mini-mization Evaluation. Journal of Telemedicine and Telecare. In Press. June 2014.

Fall 2014 pg. 14

JERRY JARVIK Friedly J, Bauer Z, Comstock B, DiMango E, Ferrara A, Huang SS, Israel E, Jarvik JG, Nierenberg AA, Ong MK, Penson D, Smith-Bindman R, Stillman AE, Vollmer WM, Warren S, Zha C, Hsia D CW, Trontell A. Challenges Con-ducting Comparative Effectiveness Research: The Clinical

And Health Outcomes Initiative in Comparative Effective-ness (CHOICE). Experience. Journal of Comparative Ef-fectiveness Research. 2014, In Press. Deyo RA, Jarvik JG, Chou R. Low Back Pain in Primary Care. British Medical Journal 349:g4266 2014. Andreisek G, Winklhofer SF-X, Deyo R, Jarvik JG, Porchet F. Consensus conference on core radiologic parameters to describe lumbar stenosis – an initiative for structured report-ing. European Radiology, 2014, In Press.

LARRY KESSLER Friedly JL, Comstock BA, Turner JA, Heagerty PJ, Deyo RA, Sullivan SD, Bauer Z, Bresnahan BW, Avins AL, Nedel-jkovic SS, Nerenz DR, Standaert C, Kessler L, Akuthota V, Annaswamy T, Chen A, Diehn F, Firtch W, Gerges FJ, Gilli-gan C, Goldberg H, Kennedy DJ, Mandel S, Tyburski M, Sanders W, Sibell D, Smuck M, Wasan A, Won L, Jarvik JG. A randomized trial of epidural glucocorticoid injections for spinal stenosis. N Engl J Med. 2014 Jul 3;371(1):11-21. doi: 10.1056/ NEJMoa 1313265. PMID: 24988555 Flum DR, Alfonso-Cristancho R, Devine EB, Devlin A, Farrokhi E, Tarczy-Hornoch P, Kessler L, Lavallee D, Pat-rick DL, Gore JL, Sullivan SD; CERTAIN Collaborative. Implementation of a "real-world" learning health care sys-tem: Washington state's Comparative Effectiveness Research Translation Network (CERTAIN). Surgery. 2014 May;155(5):860-6. doi: 10.1016/j.surg.2014.01.004. PMID: 24787113 Jarvik JG, Comstock BA, Heagerty PJ, Turner JA, Sullivan SD, Shi X, Nerenz DR, Nedeljkovic SS, Kessler L, James K, Friedly JL, Bresnahan BW, Bauer Z, Avins AL, Deyo RA. Back pain in seniors: the Back pain Outcomes using Longi-tudinal Data (BOLD) cohort baseline data. BMC Musculo-skelet Disord. 2014 Apr 23;15(1):134. doi: 10.1186/1471-2474-15-134. PMID: 24755158 PMCID: PMC4021204

GARY LYMAN Lyman GH, Benson AB, Bosserman L, Burstein HJ, Cody HS, Edge SB, Hayman JA, Newman LA, Perkins CL, Podol-off DA, Turner RR, Weaver DL, Giuliano AE: Sentinel Lymph Node Biopsy for Patients with Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Prac-tice Guideline Update, J Clin Oncol 2014; 32: 1365-1383. Lyman GH, Abella S, Pettengell R: Risk Factors for Febrile Neutropenia Among Patients with Cancer Receiving Chem-otherapy: A Systematic Review. Crit Rev Oncol Hematol 2014; 90: 190-199. Lyman GH: Impact of Venous Thromboembolism on Sur-vival in Patients with Advanced Cancer: An Unmet Clinical Need. Intern Emerg Med 2014 (in press).

JEANNINE McCUNE McCune JS, Bemer MJ, Baker KS, Gamis A, Holford NHG. Busulfan in infant to adult hematopoietic cell trans-plant recipients: A population pharmacokinetic model for

initial and bayesian dose personalization Clinical Cancer Re-search. 2014 Feb 1;20(3):754-63. doi: 10.1158/1078-0432.CCR-13-1960. Epub 2013 Nov 11. Diestelhorst C, Boos J, McCune JS, Russell J, Kangarloo SB, Hempel G. Physiologically-Based Pharmacokinetic Mod-elling of Busulfan: A New Approach to Describe and Predict the Pharmacokinetics in Adults. Cancer Chemother Pharma-col 2013 Nov;72(5):991-1000. Epub 2013 Sep 6. PMID: 24061863 Bemer MJ, Sorror M, Sandmaier BM, O’Donnell PV, McCune JS. A Pilot Pharmacologic Biomarker Study in HLA-Haploidentical Hematopoietic Cell Transplant Recipi-ents. Cancer Chemother Pharmacol 2013 Sep;72(3):607-18. Epub 2013 Aug 2. PMID: 23907443.

DONALD PATRICK Flum DR, Alfonso-Cristancho R, Devine EB, Devlin A, Farrokhi E, Tarczy-Hornoch P, Kessler L, Lavallee D, Pat-rick DL, Gore JL, Sullivan SD; CERTAIN Collaborative. Implementation of a "real-world" learning health care sys-tem: Washington state's Comparative Effectiveness Research Translation Network (CERTAIN). Surgery. 2014 May;155(5):860-6. doi: 10.1016/j.surg.2014.01.004. PMID: 24787113 Gallego CJ, Bennette CS, Heagerty P, Comstock B, Horike-Pyne M, Hisama F, Amendola LM, Bennett RL, Dorschner MO, Tarczy-Hornoch P, Grady WM, Fullerton SM, Trinidad SB, Regier DA, Nickerson DA, Burke W, Patrick DL, Jarvik GP, Veenstra DL. Comparative effectiveness of next genera-tion genomic sequencing for disease diagnosis: Design of a randomized controlled trial in patients with colorectal can-cer/polyposis syndromes. Contemp Clin Trials. 2014 Jul 2. pii: S1551-7144(14)00098-6. doi: 10.1016/j.cct.2014.06.016. [Epub ahead of print] PMID: 24997220 Andrae DA, Covington PS, Patrick DL. Item-level assess-ment of the irritable bowel syndrome quality of life question-naire in patients with diarrheal irritable bowel syndrome. Clin Ther. 2014 May 1;36(5):663-79. doi: 10.1016/j.clinthera.2014.04.009. Epub 2014 May 9. PMID: 24813429

SCOTT RAMSEY Barocas DA, Bensink ME, Berry K, Musa Z, Bodnar C, Dann R, Ramsey SD. Economic evaluation of diagnostic localization following biochemical prostate cancer recur-rence. In press, International J Tech Assess Healthcare. Seal, B, Sullivan SD, Ramsey SD, Asche CV, Shermock K, Sarma S, Zagadailov EA, Farrelly E, Eaddy M. 2014. Com-paring Hospital-Based Resource Utilization and Costs for Prostate Cancer Patients With and Without Bone Metas-tases. Applied health economics and health policy. Jul 9; Epub ahead of print. Unger, JM, Barlow WE, Martin DP, Ramsey SD, LeBlanc M, Etzioni R, Hershman DL. 2014. Comparison of Survival Outcomes Among Cancer Patients Treated In and Out of Clinical Trials. Journal of the National Cancer Institute. 106 (3): 1-13.

ANDY STERGACHIS

Sangare L, van Eijk AM, ter Kuile FO, Walson J, Stergachis A. The association between malaria and iron status or

JOSEPH BABIGUMIRA Co-Inv., (PI Frenkel) Drug-resistance testing in Kenya to improve ART suppression of HIV replication, National Institutes of Health (NIH), 2012 – 2015

Faculty — Recent Grants

supplementation in pregnancy: a systematic review and meta-analysis. PLoS ONE. 2014;Feb 14;9:e87743. Kovacs S, Hawes SE, Maley SN, Mosites E, Wong L, Stergachis A. Technologies for detecting falsified and substandard drugs in low and middle income countries. PLoS ONE. 2014. 9: e90601. Roth GA, Gillespie CW, Mokdad AA, Shen DD, Fleming DW, Stergachis A, Murray CJL, Mokdad AH. Aspirin use and knowledge in the community: a population and health facility based survey for measuring local health system per-formance. BMC Cardiovascular Disorders. 2014. 14:16.

SEAN SULLIVAN

Ramsey SD, Sullivan SD. A new model for reimbursing genome-based cancer care. The Oncologist 2014 19:1-4. Pauly M, Frank R, Sullivan SD. An economic framework for preventive care advice. In press Health Affairs 2014 Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget Impact Analysis Principles of Good Practice: Report of the ISPOR Budget Impact Analysis Good Practice II Task Force. Value in Health 2014 17:5-14

DAVID VEENSTRA Thariani R, Henry NL, Ramsey SD, Blough DK, Barlow B, Gralow JR, Veenstra DL. Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. J Comp Eff Res. 2013 May;2(3):325-34. doi: 10.2217/cer.13.15. PMID: 24236631 Feero WG, Wicklund C, Veenstra DL. The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health. JAMA. 2013 Mar 27;309(12):1235-6. doi: 10.1001/jama.2013.113. PMID: 23532238 Bennette CS, Trinidad SB, Patrick D, Amendola L, Burke W, Hisama FM, Jarvik GP, Regier DA, Veenstra DL. Return of Incidental Findings in Genomic Medicine: Measuring What Patients Value. Development of an Instrument to Measure PReferences for Information from Next-generation Testing (IMPRINT). GenetMed. 2013 Nov;15(11):873-81. PMID: 23722871

PI, Implementing Male Circumcision for HIV Preven-tion: Understanding Barriers and Incentives in a High Prevalence Rural Population in Uganda, University of Washington School of Public Health and University of Washington Center for AIDS Research (CFAR), 2013 – 2014

PI, Impact Evaluation of a Pharmacy Assistant Train-

ing Program in Malawi Barr Foundation 2014-2017

ANIRBAN BASU Co-PI, (PI Liu) Innovative Methods for Modeling Longi-tudinal Medical Costs, AHRQ, 2012-2016 Co-PI, (PI Huang) Comparative Effectiveness of Dy-namic Patterns of Glucose Lowering Therapies, AHRQ, 2012-2016

DENISE BOUDREAU PI, Metformin and Breast Cancer. National Cancer Insti-tute. 2012-2014

PI, A Survey of Adult Awareness and Reasons for Lack of Post-Fracture Osteoporotic Care. Amgen 2013-2014

Co-Inv. (PI Thummel) Pharmacogenetics in Rural and Underserved Populations. National Institute of General Medical Sciences. 2010-2015.

BRIAN BRESNAHAN PI, Evaluating issues related to CT dose exposure and exploring risk mitigation strategies, General Electric Company, 2012 – 2014 Co-Inv. (PI Friedly) Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis Patient-Centered Outcomes Research Institute (PCORI) 2013 – 2016 PI, Economic analysis of an international, multi-site randomized controlled trial of ultrasound screening? primary project sponsor (Bill and Melinda Gates Founda-tion).

BETH DEVINE PI, Use of Patient-Reported Outcome Instruments in Clinical Trials, Novartis Pharmaceuticals, 2013-2014 PI, UW-Allergan Post-Doctoral Fellowship, Allergan Pharmaceuticals, 2012- Co-Inv., Pacific Northwest Evidence-based Practice Center (EPC) IV. Four evidence-synthesis projects: 1) Im-aging Techniques for Hepatocellular Cancer; 2) Imaging Techniques for Metastatic Breast Cancer; 3) Effectiveness and Risks of Long-term Opioid Treatment of Chronic Pain; 4) Health Information Exchange, 2013-2015 Lead Co-Inv, Methods Core, CERTAIN (Comparative Effectiveness Research Translation Network) Hub, AHRQ, 2014-2015

JOSH CARLSON

Co-Inv. Personalized medicine economics research

(PriMER). 1U01AG047109-01. National Institutes of

Health. September 2013 – September 2018.

PI (UW subcontract). A Structured Approach To Prior-

itizing Cancer Research Using Stakeholders And Value

Of Information. Patient Centered Outcomes Research

Institute. Sept. 2013 – Sept. 2016.

15 PORPP

Fall 2014 pg. 16

PI Abridged Topic Development of PCORI Re-

search Topics: Improving Health Systems Program.

Pacific Northwest Evidence-based Practice Center. Agen-

cy for Healthcare Research and Quality. Aug. 2013 –

Aug. 2014.

LOUIS GARRISON, JR. Principal Mentor, UW-Pfizer Post-Doctoral Fellowship, 2014-2016. Co-Inv. (PI-Chung) University of Nairobi HIV Capacity Building Fellowship. USAID, 2014-2018 Co-Inv. (PI-Bresnahan) Saving Lives at Birth: A Grand Challenge for Development. USAID, 2014-2015 Co-Inv., (PI Frenkel), Drug-resistance testing in Kenya to improve ART suppression of HIV replication, Na-tional Institutes of Health (NIH), 2012 – 2015

SHELLY GRAY PI (UW subcontract, Larson PI), Longitudinal Effect of Anticholinergic Polypharmacy on dementia and neuro-pathology 2012-2014 Co-Inv., (Larson PI) Alzheimer's Disease Patient Regis-try NIA 2009-2014 Co-Inv., (Dublin PI) Opioids, benzodiazepines, general anesthesia & risk of dementia and other brain outcomes Branta Foundation 2012-2015

DONALD PATRICK PI, Biobehavioral Cancer Prevention and Control Train-ing Program NIH/NCI 2011-2016 Co-Inv., (PI Buchwald) Center for Native Population Health Disparities NCI 2010-2015 Co-Inv., (PI Jarvik) Clinical sequencing in cancer: Clini-cal, ethical, and technological studies NIH 2011-2015

SCOTT RAMSEY Co-Investigator/Co-Chair, “SWOG Network Group Operations Center of the NCTN” submitted to Oregon Health and Sciences University (OHSU), National Cancer Institute (NCI) for funding period 03/01/2014 – 02/28/2019 PI, “A Multi-State Study of Cancer Treatment and Out-comes Among American Indians.” National Cancer Insti-tute (NCI), R01 CA125231. 9/10/2007 – 4/30/2015

ANDY STERGACHIS PI, Pharmacy & Supply Chain Strengthening Program to Improve Access to Essential Medicines in Malawi

Barr Foundation via VillageReach

PI, Operational Planning for Pharmacy-Local Health

Jurisdiction Memorandum of Understanding

Department of Health, State of Washington

PI, Systems to Improve Access to Pharmaceuticals and

Services: Namibia, Ukraine, 2014 USAID via Manage-

ment Sciences for Health

SEAN SULLIVAN

PI, CHASE K12 Training, 2014-2019, AHRQ

Co-Inv. (PI Linda Teri) From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Ser-vices. (National Institute of Aging) PI, K-12 Mentored Career Development Program in Patient-Centered Outcomes Research (AHRQ) July 2012 to June 2014.

PORPP would like to acknowledge our many sup-

porters of this past year. Our accomplishments

would not have been possible without these gener-ous educational grants and gifts.

Allergan

Bayer AG

Jonathan & Christine Campbell

Josh & Amy Carlson

Beth Devine, PharmD, MBA, PhD

Joseph DiCesare

Eli Lilly & Company

Pete and Kathy Fullerton

Louis and Fran Garrison, Jr.

GE Foundation

GE Healthcare

Genentech, Inc.

GlaxoSmithKline

Thomas Hazlet, PharmD, DrPH

Mitchell and Mandy Higashi

Mark & Pamela Holzemer

Cara McDermott & Scott Gardner

Novartis Pharmaceuticals Corp.

Pacira Pharmaceuticals, Inc.

Pfizer Inc.

Scott & Ellen Ramsey

Joshua Roth

Andy and Joanne Stergachis

Sean and Catrena Sullivan

David and Julie Veenstra

Bruce Wang, PhD

Washington Research Foundation

Todd Williamson

PORPP Health Technology Fund (Eli Lilly,

GE Healthcare, Genentech, Glaxo- SmithKline, Novartis, Ortho-McNeil, Pfizer, Roche, Sanofi-Aventis)

Gifts

Co-Director, Pacific Northwest Evidence-Based Prac-tice Center (AHRQ) August 2012 to July 2017

DAVID VEENSTRA

PI Personalized Medicine Economics Research (PriMER), NIH, 2013-2018.

Co-Inv. (PI Sullivan) CHASE K12 Training, 2014-2019 AHRQ

Co-Inv. (PI Burke) Center for Genomics and Healthcare Equality, 2010-2015, NIH/NGRI

Co-Inv. (PI Thummel) Pharmacogenetics in Rural and Underserved Populations, 2010-2015, NIGMS